Abstract

ALDH is an enzyme involved in different cellular processes, including cancer. It has been shown that a cellular subpopulation with high ALDH activity (ALDHHIGH) within a tumor is related to functional capabilities such as stemness, chemoresistance, and tumorigenicity. However, few studies have focused on determining the mechanisms behind ALDH activity within the cells. Previously, our group reported that ALDHHIGH cells have higher tumorigenicity in Cervical Cancer (CC) cell lines. Based on this, we were interested to know the molecular mediators of the ALDHHIGH cells, specifically β-catenin, inasmuch as β-catenin is regulated through different pathways, such as Wnt signaling, and that it acts as a transcriptional co-activator involved in cancer progression. In this work, we show that the increase in ALDHHIGH cell percentage is reverted by β-catenin knockdown. Consistently, upon GSK3-β inactivation, a negative regulator of β-catenin, we observed an increase in ALDHHIGH cells. Additionally, we observed a low percentage of cells positive for Fzd receptor, suggesting that in our model there is a low capacity to respond to Wnt ligands. The analysis of ALDHHIGH cells in a sphere formation model demonstrated the active state of AKT. In accordance with this, impairment of AKT activity not only reduced β-catenin active state, but also the percentage of ALDHHIGH cells. This corroborates that AKT acts upstream of β-catenin, thus affecting the percentage of ALDHHIGH cells. In conclusion, our results show that ALDHHIGH cells are dependent on β-catenin, in spite of the Wnt pathway seems to be dispensable, while AKT emerges as central player supporting a mechanism in this important axis that is not yet well known but its analysis improves our understanding of ALDH activity on CC.

Highlights

  • The Aldehyde dehydrogenase (ALDH) enzyme catalyzes the conversion of endogenous and exogenous aldehydes to carboxylic acids, being a key factor for improving the detoxification and chemoresistance associated with cancer relapse

  • ALDH is an enzyme superfamily encoded by 19 genes and 3 pseudogenes, described in the human genome

  • There are several isoforms and levels depending on the cellular context, the cells with the highest ALDH activity partially explain drug resistance in cancer [1, 20]

Read more

Summary

Introduction

The Aldehyde dehydrogenase (ALDH) enzyme catalyzes the conversion of endogenous and exogenous aldehydes to carboxylic acids, being a key factor for improving the detoxification and chemoresistance associated with cancer relapse. Encompassed by a family of isoenzymes, ALDH proteins have multiple functions in cancer cells, including proliferation, differentiation, and pharmacological resistance. There is evidence that high ALDH activity (ALDHHIGH) improves stemness-related characteristics reflected on Cancer Stem Cells (CSC). Employing spheres formation cultures, it has been possible to enrich CSC-associated characteristics identified by ALDHHIGH activity, and through other molecular markers associated with CSC populations, for instance CD44, CD24, LGR5/GPR49, among others. In Cervical Cancer (CC), spheres cultures from cell lines display higher levels of CSC-related molecular markers as compared with monolayer cultures, such as Oct-4, Nanog, and CD49f. Studies from our and other groups recognized that ALDHHIGH cells were enriched in spheres cultures and are associated with tumorigenic capacities and resistance to cisplatin [3,4,5]

Objectives
Methods
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call